Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Marie Skłodowska-Curie Action · Running

immunoMet Deciphering immune evasion mechanisms of metastatic cancer cells using CRISPRa-inducible reporters

Coordinator
Forschungsinstitut Fur Molekulare Pathologie Gesellschaft Mbh, Austria
Runs
1 September 2024 to 30 June 2027
Status
Running
EU funding
€199k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101108907

What the project is doing

In the project's own words, from its summary on CORDIS.

Most cancer patients are resistant to immunotherapies, especially patients with liver and bone metastases. This suggests that during metastasis, cells acquire additional immune evasion mechanisms that dictate susceptibility to immunotherapies. Current immunotherapies initiate T cell-mediated killing of cancer cells. However, combining them with agents that target other immune cells in the body, such as natural killer (NK) cells, may be more effective.

Whether immune evasion mechanisms of metastatic cells differ between organs and whether these mechanisms can be targeted to improve immunotherapeutic strategies remains unknown. The first aim of this proposal is to leverage a molecular barcoding technique named CaTCH (CRISPRa tracing of clones in heterogenous cell populations) to search for new mechanisms of NK cell immune evasion. CaTCH enables tracing metastatic cancer cells in vivo and isolating clones in a barcode-specific manner for subsequent characterization and functional experiments.

We engineered a human non-small-cell lung cancer model with a complex CaTCH barcoding library. Subsequently, we injected the cells into mice harboring NK cells and mice having no NK cells in an experimental metastasis assay. We identified several barcoded clones enriched in specific organs under immune pressure. I aim to investigate this dataset to find novel mechanisms of NK cell immune evasion in the metastatic environment.

In the second aim, I will combine molecular barcoding with replicative history tracing of cells to identify cancer clones that evade immune-mediated dormancy in the metastatic niche. I will compare the transcriptional and molecular profiles of dividing cells high in abundance to dividing cells low in abundance to find novel mediators of immune-mediated dormancy. The successful implementation of these aims will uncover new immune evasion strategies of metastatic cells that will pave the way for novel immunotherapeutic strategies for cancer patients.

Topics

Who is involved

OrganisationCityCountryRole
Forschungsinstitut Fur Molekulare Pathologie Gesellschaft MbhWienAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI